Shenzhen Yuanzheng Technology Co., Ltd., established on 1993-07-27, Business scope includes general business items:,The licensing program is:car diagnostics,detection,repair,Development of maintenance equipment and related software,Production,Sales and Leasing;Development of automotive electronics,Production,Sales and Leasing;lease of own property;in the advertising business;Information network service(Does not contain franchise,Exclusive control,Exclusives and restricted items);Operation Shenzhen Trade Management Registration Certificate No.17No<Self-support import and export business level certificate>prescribed import and export business.

Daotong Technology has been deeply involved in the field of global automobile intelligent diagnosis and testing. It has built comprehensive automobile diagnostic products, TPMS series for automobile tire pressure monitoring systems, and automobile tire pressure monitoring systems by keeping up with the development trend of automobiles and continuous product innovation. The ADAS series of intelligent assisted driving systems is one of three major product lines. Simultaneously, it began to provide integrated intelligent maintenance cloud services based on the diagnosis and maintenance data and cases accumulated over the years. It was founded in 2004 and is listed on the Shanghai Stock Exchange's Science and Technology Innovation Board in February 2020.

Cordio Medical offers to create and deliver game-changing solutions for monitoring health conditions using a patient's voice. They offer transcription of a patient free speech into a smartphone app. They assist physicians in preventing patient deterioration and hospitalization while keeping the patient at home by assisting them in identifying and mitigating condition worsening.

Provides diagnostic and therapeutic services for urological disorders

Shenzhen Xingka Software Technology Development Co., Ltd., established on 2020-04-10, Business scope includes general business items:Computer software and hardware development and sales,Internet network technology development,technical sales,Technical Consulting and Technical Services,Development and sales of auto parts.,The licensing program is:

Shenzhen Star Card Technology Co., Ltd., established on 2019-08-01, Business scope includes general business items:Technology development and sales of computer software and hardware;Internet network technology development,technical sales,Technical Consulting and Technical Services;Development and sales of auto parts;Production of automotive diagnostic equipment;Domestic Trade,Technology and goods import and export business.New energy vehicle production and testing equipment sales;Manufacturing of auto parts and accessories.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license),The licensing program is:Motor Vehicle Repair and Maintenance.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

OTraces Inc. is a provider of advanced oncology diagnostic systems. Manufactured in Nevada and Maryland USA, the company’s CDx Chemistry System™ elevates clinical blood analysis to new levels of precision and sophistication. Designed for cost-effective operation in the clinical laboratory, the company’s instrument group advances the science of cancer detection through the analysis of blood serum. The extreme sensitivity of protein detection possible with the CDx Chemistry System is combined with a proprietary bioinformatics engine for multi-marker profiling for the presence of cancer. The company’s first test kit – the BC Sera Dx™ panel for breast cancer detection and screening has completed Phase II of its validation in Russia with very successful results and after a small final validation protocol will be released in the fall of 2013. The prostate cancer test PC Sera Dx will under go validation also this fall. Test kits for additional cancers including ovarian, prostate, colon and lung are under development.

Toshiba Energy Systems & Solutions Corporation is a supplier of integrated energy and medical solutions. With its long experience and expertise in a wide range of power generation and, transmission systems and energy management technology, the company delivers innovative, reliable and efficient energy solutions across the globe.

Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the Central Nervous System (CNS). We combine the efforts of medicinal chemists, pharmacologists, biologists and clinical development scientists into a vibrant team that translates world-class research expertise into novel drugs. The company's lead product, ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (DPPM) designed to treat multiple deficits in patients with schizophrenia while lacking the side-effects of existing antipsychotic drugs. ITI has also developed a state of the art technology platform, called CNSProfile™ that is capable of generating a unique molecular signature for drug compounds. This profile provides us with a proprietary window into the intracellular action of CNS drugs or drug candidates. We use this tool to fingerprint the intracellular molecular actions of existing drugs and to drive our internal drug discovery and development. Our technology has also enabled the company to examine the toxic effects of brain damaging nerve agents, and as a result, we are involved in collaborative efforts with several military and contract organizations to develop antidotes to chemical warfare agents. Based upon our understanding of the Central Nervous System we have discovered novel drug candidates with promise for treating the panoply of symptoms associated with the transition from peri-menopausal to post-menopausal states. Intra-Cellular Therapies was founded in 2002 by Drs. Paul Greengard, Sharon Mates and Allen Fienberg. The company is headquartered in New York City.

Senex Biotechnology, Inc. engages in discovering and developing therapeutic agents to treat cancer, viral diseases, and age-related diseases. The company offers SNX2 non-cytotoxic molecules compounds that are developed against viral diseases, age-associated diseases, and as add-ons to existing anticancer drug regimens; and SNX9 cyclin-dependent kinase inhibitor pathway inhibitors that are developed for cancer treatment. It offers therapeutic agents to treat cancer and a range of diseases associated with the aging process, such as Alzheimer’s disease, renal disease, atherosclerosis, and arthritis. The company was incorporated in 2002 and is based in Columbia, South Carolina.

Korea Institute of Industrial Technology is a South Korean private company that operates as research institute.

Designs, engineers, manufactures, distributes and sells vehicles

Vascular Solutions develops clinical solutions for coronary and vascular procedures. They provide products and services to cardiologists, interventional radiologists, electrophysiologists, and vein specialists through the distributor network. Their products include catheters, hemostats, and vein products.

AhnLab is a cloud security technology provider that develops information security solutions and services for consumers, enterprises, and small and medium businesses worldwide. It delivers a comprehensive security lineup, including proven, world-class antivirus products for desktops and servers, mobile security products, online transaction security products, network security appliances, and consulting services. AhnLab has established its market position and manages sales partners in many countries worldwide. Based on its cloud computing strategy, AhnLab’s technologies and solutions converge into a single platform to cope with evolving IT security challenges. It delivers comprehensive, coordinated protection against a wide variety of threat sources. AhnLab was founded in 1995 by Charles Ahn and is headquartered in Seoul.

Shenzhen Yuanzheng Software Development Co., Ltd., established on 2005-04-26, Business scope includes general business items:computer software,hardware development,Sales;Computer network engineering and computer technology development and consulting.(The above does not include franchise,Exclusive control,Exclusives and restricted items).Operating import and export business.,The licensing program is:

Hangzhou Yisheng Medical Technology Co., Ltd., established on 2016-08-26, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Biochemical product technology research and development;Information Consulting Service(Not including licensing information consulting services);integrated circuit manufacturing;IC Design;IC sales;Integrated circuit chip and product manufacturing;Integrated circuit chip design and service;Integrated circuit chips and product sales;Manufacturing of Special Equipment for Semiconductor Devices;Professional Design Services;Electronic special material manufacturing(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Technology Import and Export;Import and export;Drug import and export;Drug internet information service;Drug Wholesale;pharmaceutical production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

L'Air Liquide SA engages in gas supply for large industry and health businesses. It operates through the following segments: Gas & Services, Engineering & Construction, and Global Markets & Technologies. The Gas & Services segment activities are organized by geographical areas, which determine sales policies and development projects. The Engineering & Construction segment designs, develops and builds industrial gas production plants. The Global Markets & Technologies segment focuses on new markets which require a global approach, drawing on science, technologies, development models, and usages related to digital transformation. The company was founded by Georges Claude and Paul Delorme on November 8, 1902 and is headquartered in Paris, France.

Our United consists of more than 10 professional departments such as technology and R&D, production and operation, marketing and sales, regulations and quality, and the Institute of Medical Research (Xi'an), Xi'an Dawei Technology Innovation Center, and the United States Joint Research and Development Center (San Francisco). And other professional institutions; Da Ma Group owns a number of branches of Shenzhen Aowo Medical New Technology Development Co., Ltd., Dafei Group Beijing R&D Center, Wuhan Digital Knife Medical Co., Ltd., Dazhi Zhizhi Center; Da Ma Group also owns AVIC 363 Hospitals, Chang'an Hospital and Ovo (Xi'an) Innovation Center and many other training centers.